Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
1. Bio-Rad's Q2 earnings were $2.61, surpassing expectations of $1.76. 2. Quarterly sales reached $651.6 million, beating estimates of $615.1 million. 3. FY2025 sales guidance narrowed to $2.567-$2.593 billion from $2.541-$2.606 billion. 4. Successful acquisition of Stilla Technologies enhances Bio-Rad's product offerings. 5. Shares jumped 19.5% post-announcement, closing at $289.03.